MESO
NASDAQMesoblast Limited
Price$17.36+0.85 (+5.15%)
01:30 PM07:45 PM
News · 26 weeks58+900%
2026-01-182026-07-12
Mix1790d
- SEC Filings8(47%)
- Other7(41%)
- Insider2(12%)
Latest news
25 items- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainNEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial. Silviu Itescu, Chief Executive of Mesoblast, said: "Completing our target of treating at least 300 patients in the placebo-controlled pivotal back pain
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Obrien James Michael4 - MESOBLAST LTD (0001345099) (Issuer)
- PRRyoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. "We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections," said Mesoblast Chief Executive Dr. Silviu Itescu. Dr. Itescu added: "We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major U.S. pediatric centers. Our capital position is strong, operati
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADsNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). Rexlemestrocel-L has received Orphan Drug Designation for prevention of life-threatening major mucosal bleeding events and has Regenerative Medicine Adva
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Draws US$50 Million from Five-Year Non-Dilutive FacilityOptimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. Mesoblast had US$122 million cash at March 30, 2026. In aggregate Mesoblast is well funded to invest in its commercial operations and growth pipeline, and optimize its capital structure by retiring the higher cost NovaQuest Capital Management LLC debt facility
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItIssued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 MillionAchieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. "We've had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year's launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has succes
- INSIDERNew insider Cobley Lynette Elizabeth claimed ownership of 63,000 units of Ordinary Shares (SEC Form 3)3 - MESOBLAST LTD (0001345099) (Issuer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back PainNEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration. The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell ProductsNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration. Mesoblast's MSC technology platforms, including the first and on
- INSIDERSEC Form 4 filed by George Gregory4 - MESOBLAST LTD (0001345099) (Issuer)
- INSIDERSEC Form 4 filed by George Gregory4 - MESOBLAST LTD (0001345099) (Issuer)
- PRMesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTIONWorking with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil® is the first mesenchymal str
- PRMesoblast R&D Day Features Significant Commercial Progress & Platform InnovationMesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for inflammatory back pain and heart failure Announces close of enrollment for Phase 3 trial for CLBP at the end of this month Highlights label extension strategy for Ryoncil® in adult and pediatric rare diseases: - Adult SR-aGvHD trial cleared by central institutional review board (IRB), first sites to be activated this quarter - FDA cleared IND to directly proceed to registrational trial for approval of Ryoncil® in children with Duchenne muscular dystrophy (DMD) Announces acquisition of a patented
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
MESO FAQ
7 questionsWhat does Mesoblast Limited do?
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic...Where does MESO stock trade?
Mesoblast Limited (MESO) is listed on NASDAQ.What sector and industry is MESO in?
Mesoblast Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Mesoblast Limited go public?
Mesoblast Limited (MESO) completed its IPO in 2015.What are analysts saying about MESO?
Mesoblast Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-11-25. Recent price targets range from $1100.00 to $1200.00.What companies are similar to MESO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MESO side-by-side with any of them on Quantisnow.How can I track MESO on Quantisnow?
Quantisnow aggregates Mesoblast Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MESO to receive live email and push alerts on every new disclosure.